AiCuris has announced the publication of results from a preclinical study assessing the antiviral efficacy of the Company’s proprietary immune modulator AIC649 as well as its potential to induce functional cure in animal models for chronic hepatitis B.
AIC649 is an inactivated parapoxvirus ovis (iPPVO) particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses. Currently, AIC649 is being investigated in a clinical Phase I study in patients with chronic hepatitis B.
To analyse the antiviral efficacy, hepatitis B transgenic mice were treated either twice-weekly with AIC649 or twice daily with “gold standard” Tenofovir or vehicle over a period of 29 days. Both treatment regimens showed a significant reduction of hepatitis B virus (HBV) titer compared to the control group. Noteworthy, the twice-weekly treatment with AIC649 showed an antiviral effect similar to the twice-daily treatment with Tenofovir.
Read more....
Labels: AiCuris, drug development